Roivant Sciences shares climbed to $40.965, up 17.28% from the prior close of $34.93, placing the company within a fraction of its 52-week high of $41.35 during the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026.
The gain came as CEO Matt Gline highlighted a pipeline of clinical catalysts and regulatory milestones that are reshaping investor expectations for the unprofitable biotech, which carries a market value of just under $30 billion and maintains a current ratio of 16.72 despite trailing-twelve-month losses of $0.49 per share and revenue of $7.5 million.
Roivant announced earlier in the day that it had enrolled approximately 100 to 120 patients in the Phase IIb PHocus trial of mosliciguat, an inhaled soluble guanylate cyclase (sGC) activator targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD). The data showed a 56% placebo-adjusted improvement in pulmonary vascular resistance — described by Gline as "the deepest PVR reduction ever observed in any pulmonary hypertension study." Mosliciguat is administered as a single daily inhalation of dry powder.
Gline noted that the global PH-ILD patient population is estimated at roughly 200,000, with United Therapeutics placing conservative U.S. estimates at 30,000 patients. He pointed to Merck-Bayer's systemically administered sGC drug Adempas as a comparable product that reached approximately $2 billion in peak sales, suggesting meaningful upside for an inhaled alternative with potentially better tolerability.
Roivant also reported on the Phase IIb readout of IMVT-1402 for difficult-to-treat rheumatoid arthritis, in which about 50% of ACR20 responders progressed to ACR70 and roughly two-thirds reached ACR50 in the open-label first period. The drug targets patients who have failed at least two of three major drug classes — IL-6 inhibitors, TNF inhibitors, and JAK inhibitors — a population Gline placed at 75,000 or more patients in the U.S.
Other upcoming catalysts include registrational data for Graves' disease and myasthenia gravis, full-year LISRAYA commercialization experience in dermatomyositis, uveitis data, CLE proof-of-concept results, and FDA feedback on the rheumatoid arthritis program. LISRAYA (brepocitinib), a dual JAK1/TYK2 inhibitor, received FDA approval within the week preceding the conference.
Gline closed the session by noting, "This is a you-don't-have-to-outrun-the-bear situation," adding that the company's rare marathon "ends with the right to begin another marathon immediately."
